Previous Close | 370.58 |
1-Year Change | 72.73% |
6-Months Change | 15.45% |
3-Months Change | 3.17% |
Moving Avg (50d) | 362.89 |
Moving Avg (200d) | 338.71 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 17.4B |
Beta (3-Years) | 0.37 |
Revenue Growth (ttm) | 18.51% |
Net Profit Margin (ttm) | 40.69% |
Return On Assets (ttm) | 12.77% |
EPS (ttm) | 18.13 |
PE Ratio (ttm) | 20.44 |
Dividend Yield | % |
Asset Description: | United Therapeutics Corporation |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-12-17 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
363.168 | 352.051 | 344.639 | 333.522 | 314.993 | 296.464 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities... Wikipedia